RIGL Stock Analysis: Buy, Sell, or Hold?
RIGL - Rigel Pharmaceuticals Inc. (New)
$29.01
-2.91 (-9.12%)
▼
5d:
+11.41%
30d:
-8.69%
90d:
-15.47%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Smart Money Accumulation
RIGL is down 11.3% this week, but smart money is accumulating calls. Top strike: $36 2026-06-18 with 153 OI. Call ratio: 79% View Scanner →
Strength: 8.5/10
Get Alerted When RIGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
10 traders called RIGL this week
95% bullish • 1 bearish
95% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RIGL trading at deep discount. Market pricing in -7.8% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: RIGL trading at deep discount. Market pricing in -7.8% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$52.97
Based on 7.4% avg growth
INTRINSIC VALUE TODAY
$32.89
11.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RIGL is currently trading at $29.01, which is considered slightly low relative to its 30-day fair value range of $27.70 to $31.50. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.3) compared to its historical average (8.1). Remarkably, the market is currently pricing in an annual earnings decline of 7.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, RIGL is in a strong downtrend. Immediate support is located at $25.45, while resistance sits at $33.01. Short-term momentum is weak, with the stock down 9.1% recently.
Market Sentiment: RIGL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $53.20 (+83.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RIGL is in a strong downtrend. Immediate support is located at $25.45, while resistance sits at $33.01. Short-term momentum is weak, with the stock down 9.1% recently.
Market Sentiment: RIGL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $53.20 (+83.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$27.70 -
$31.50
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.1%)
- BULLISH: Trading 83.4% below Wall St target ($53.20)
Trading Range Analysis
30-Day Trading Range
$27.70 -
$31.50
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$25.45
Resistance Level
$33.01
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.33
Wall Street Target
$53.20
(+83.4%)
Revenue Growth (YoY)
10.3%
Earnings Growth (YoY)
-30.2%
Profit Margin
121.5%
Valuation Discount vs History
-7.8% cheaper
PE vs Historical
6.3 vs 8.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.8%
(market-implied from PE analysis)
1-Year Target
$26.75
(-8%)
2-Year Target
$24.66
(-15%)
3-Year Target
$22.74
(-22%)
3-Yr Target (if PE normalizes)
(PE: 6→8)
$29.09
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 10.8%)
$137.53
(+374%)
Base:
(SPY PE: 6.3, Growth: 10.8%)
$39.45
(+36%)
Bear:
(PE: 5.4, Growth: 10.8%)
$33.53
(+16%)
📈
Valuation based on Current Earnings
Trailing PE: 1.65 | Current EPS (TTM): $19.29
Bull Case
$17.56
(-40%)
Analyst growth -50.0%, PE expands to 1.8
Base Case
$15.96
(-45%)
Market implied -50.0%, PE stable at 1.7
Bear Case
$21.71
(-25%)
Severe decline -20.0%, PE contracts to 1.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.3 to 8.1
Stabilization Target:
$37.12
(+27.9%)
PE Expansion Potential:
+27.9%
Share & Embed Analysis
Last updated: May 18, 2026 8:26 AM ET
Data refreshes hourly during market hours. Next update: 9:26 AM
Data refreshes hourly during market hours. Next update: 9:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RIGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Walter H Moos
SELL
4000 shares
2026-02-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
Advanced RIGL Option Strategies
Professional options setups generated by AI based on today's RIGL price and gamma walls.
